RhumbLine Advisers’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.73M | Sell |
107,438
-3,249
| -3% | -$173K | ﹤0.01% | 1335 |
|
|
2025
Q1 | $4.48M | Buy |
110,687
+5,001
| +5% | +$202K | ﹤0.01% | 1416 |
|
|
2024
Q4 | $2.94M | Buy |
105,686
+1,310
| +1% | +$36.4K | ﹤0.01% | 1691 |
|
|
2024
Q3 | $2.99M | Sell |
104,376
-2,962
| -3% | -$85K | ﹤0.01% | 1680 |
|
|
2024
Q2 | $2.52M | Buy |
107,338
+24,940
| +30% | +$585K | ﹤0.01% | 1769 |
|
|
2024
Q1 | $2.08M | Buy |
82,398
+11,699
| +17% | +$296K | ﹤0.01% | 1897 |
|
|
2023
Q4 | $1.65M | Sell |
70,699
-85
| -0.1% | -$1.99K | ﹤0.01% | 2006 |
|
|
2023
Q3 | $3.58M | Buy |
70,784
+9,610
| +16% | +$486K | ﹤0.01% | 1534 |
|
|
2023
Q2 | $2.86M | Buy |
61,174
+6,303
| +11% | +$294K | ﹤0.01% | 1707 |
|
|
2023
Q1 | $2.1M | Buy |
54,871
+3,158
| +6% | +$121K | ﹤0.01% | 1784 |
|
|
2022
Q4 | $2.83M | Buy |
51,713
+9,452
| +22% | +$518K | ﹤0.01% | 1608 |
|
|
2022
Q3 | $1.44M | Buy |
42,261
+2,675
| +7% | +$91.1K | ﹤0.01% | 1948 |
|
|
2022
Q2 | $374K | Buy |
39,586
+13,166
| +50% | +$124K | ﹤0.01% | 2637 |
|
|
2022
Q1 | $375K | Buy |
26,420
+765
| +3% | +$10.9K | ﹤0.01% | 2550 |
|
|
2021
Q4 | $543K | Sell |
25,655
-546
| -2% | -$11.6K | ﹤0.01% | 2470 |
|
|
2021
Q3 | $586K | Buy |
26,201
+1,175
| +5% | +$26.3K | ﹤0.01% | 2473 |
|
|
2021
Q2 | $621K | Buy |
25,026
+11,376
| +83% | +$282K | ﹤0.01% | 2459 |
|
|
2021
Q1 | $396K | Sell |
13,650
-750
| -5% | -$21.8K | ﹤0.01% | 2594 |
|
|
2020
Q4 | $372K | Buy |
14,400
+1,270
| +10% | +$32.8K | ﹤0.01% | 2570 |
|
|
2020
Q3 | $404K | Buy |
13,130
+1,684
| +15% | +$51.8K | ﹤0.01% | 2386 |
|
|
2020
Q2 | $285K | Buy |
+11,446
| New | +$285K | ﹤0.01% | 2595 |
|